Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME4RA8)

• Drug Name: Amodiaquine Drug Info
• Synonyms: Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquinum; Basoquin; CQA; Camochin; Camoquin; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin; Sunoquine; Amodiaquine hydrochloride; Amodiaquine USP24; SN 10751; AMODIAQUINE, FLAVOQUINE; Amodiaquina [INN-Spanish]; Amodiaquinum [INN-Latin]; CAM-AQ 1; CAM-AQI; Cam-AQ1; Camoquin (TN); Flavoquine (TN); SN 10,751; WR-002977; Amodiaquine (USAN/INN); Amodiaquine [USAN:INN:BAN]; Amodiaquine, ring-closed; S. N. 10751

Indication

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[1]
Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[2]
Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[2]

• Therapeutic Class: Antimalarials
• Cross-matching ID:
  PubChem CID: 2165
  ChEBI ID: CHEBI:2674
  CAS Number: CAS 86-42-0
  TTD Drug ID: DME4RA8
  VARIDT Drug ID: DR00976
  INTEDE Drug ID: DR0102

Molecule-Related Drug Atlas

Drug(s) Targeting Histamine N-methyltransferase (HNMT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diphenhydramine	DMKQTBA	Hyperemesis gravidarum		Approved	[14]
Metoprine	DM5GQD7	Advanced cancer	2A00-2F9Z	Phase 2	[14]
(L-)-S-adenosyl-L-homocysteine	DMDUN83	Discovery agent	N.A.	Investigative	[15]
4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE	DM68S9F	Discovery agent	N.A.	Investigative	[14]

Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[16]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[17]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[18]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[19]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[20]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[21]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[22]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[23]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[24]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[42]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[43]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[44]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[45]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[46]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[47]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[48]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[49]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[50]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[51]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[26]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[27]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[27]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[28]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[29]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[30]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[31]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[27]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[32]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[33]

Drug(s) Metabolized By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[34]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[18]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[20]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[22]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[23]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[35]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[36]
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[37]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[38]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[37]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[42]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[52]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[53]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[54]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[55]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[38]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[36]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[56]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[57]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[58]

Drug(s) Metabolized By Cytochrome P450 102A1 (cyp102)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[7]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[39]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[40]
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[7]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[41]
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[41]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[7]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[39]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[39]
GEA-6414	DM8J0MK	N. A.	N. A.	Phase 1/2	[39]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[59]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[59]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[59]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[60]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[61]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[62]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[63]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[64]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[65]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[66]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[68]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[13]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[69]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[60]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[70]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[13]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[71]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[69]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[13]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[72]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[69]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[73]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[60]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[13]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[62]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[13]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[72]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[66]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[74]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[9]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[75]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[9]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[9]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[76]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[77]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[78]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[9]

Drug(s) Affected By Interleukin-1 alpha (IL1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[9]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[9]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[81]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[9]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[83]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[9]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[85]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[88]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[89]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[90]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[91]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[92]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[93]

Drug(s) Affected By Retinoblastoma-associated protein (RB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[94]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[95]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[96]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[97]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[98]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[99]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[100]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[101]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]

Drug(s) Affected By Cathepsin D (CTSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[104]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[105]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[106]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[107]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[108]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[109]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[110]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[111]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[112]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[113]

Drug(s) Affected By Procathepsin L (CTSL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[115]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[116]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[117]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[118]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[119]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[115]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[120]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[121]

Drug(s) Affected By Cathepsin B (CTSB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[122]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[123]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[77]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[125]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[126]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[127]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[128]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[129]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[130]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[131]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[132]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[9]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[9]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[9]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[133]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[77]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[9]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[134]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[133]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[135]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[136]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[137]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[138]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[66]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[139]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[140]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[141]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[142]

Drug(s) Affected By Bone morphogenetic protein 6 (BMP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[9]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[9]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[9]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[9]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[9]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[9]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[144]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[9]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[145]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[146]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[147]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[142]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[148]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[149]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[97]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[150]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[151]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[152]

Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[153]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[154]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[155]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[156]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[157]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[158]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[159]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[160]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[9]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[162]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[163]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[164]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[165]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[97]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[52]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[166]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[167]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[168]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[169]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[170]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[171]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[172]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[88]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[173]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[174]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[175]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[176]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[177]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[178]

Drug(s) Affected By Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[179]
Selenium	DM25CGV	N. A.	N. A.	Approved	[180]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[9]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[78]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[181]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[182]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[9]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[9]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[9]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[9]

Drug(s) Affected By Transcription factor E2F1 (E2F1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[183]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[184]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[185]
Selenium	DM25CGV	N. A.	N. A.	Approved	[124]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[169]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[100]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[77]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[78]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[135]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[178]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[139]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[123]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[187]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[97]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[98]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[188]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[168]

Drug(s) Affected By Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[141]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[123]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[189]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[190]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[191]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[192]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[193]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[123]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[194]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[195]

Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[9]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[9]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[9]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[9]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[9]
Amikacin	DM5PDRB	Bacteremia	1A73	Approved	[9]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[9]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[9]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[9]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[112]

Drug(s) Affected By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tegafur	DM31ZQM	Solid tumour/cancer	2A00-2F9Z	Approved	[196]
Methoxsalen	DME8FZ9	Cutaneous T-cell lymphoma	2B01	Approved	[197]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[198]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[199]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[200]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[201]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[202]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[203]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[204]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[205]

Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fomepizole	DM6VOWQ	Athylene glycol or methanol poisoning	NE61	Approved	[206]
Ademetionine	DMYQDBO	Hepatic fibrosis	DB93.0	Approved	[207]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[66]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[208]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[209]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[200]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[210]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[113]
Didanosine	DMI2QPE	Human immunodeficiency virus infection	1C62	Approved	[66]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[72]

Drug(s) Affected By Myeloperoxidase (MPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[66]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[211]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[66]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[66]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[212]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[213]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[214]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[215]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[216]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[217]

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[73]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[218]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[219]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[220]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[221]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[222]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[223]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[224]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[225]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[226]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[227]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[228]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[69]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[13]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[13]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[229]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[230]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[231]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[232]

Drug(s) Affected By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[227]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[67]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[230]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[230]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[233]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[234]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[235]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[112]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[113]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[236]

Drug(s) Affected By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[237]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[112]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[234]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[238]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[239]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[240]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[241]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[242]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[243]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[244]

Drug(s) Affected By Cytochrome P450 2A13 (CYP2A13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[199]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[208]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[208]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[245]
HELENALIN	DMMCI4H	N. A.	N. A.	Terminated	[246]
Acenaphthenol	DMT3QYZ	N. A.	N. A.	Investigative	[247]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[248]
BRN-3548355	DM4KXT0	N. A.	N. A.	Investigative	[248]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[249]
9-phenanthrol	DMJFBQ1	Discovery agent	N.A.	Investigative	[250]

Drug(s) Affected By Cytochrome P450 2C18 (CYP2C18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[251]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[251]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[252]
Lansoprazole	DMXYLQ3	Gastric ulcer	DA60	Approved	[253]
Warfarin	DMJYCVW	Atrial fibrillation	BC81.3	Approved	[254]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[255]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[208]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[112]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[256]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[257]

Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[258]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[259]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[260]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[261]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[262]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[263]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[60]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[13]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[264]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[265]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine N-methyltransferase (HNMT)	TT2B6EV	HNMT_HUMAN	Inhibitor	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[4]
Cytochrome P450 1B1 (CYP1B1)	DE9QHP6	CP1B1_HUMAN	Substrate	[4]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[5]
Glutathione S-transferase mu-4 (GSTM4)	DERQ52Z	GSTM4_HUMAN	Substrate	[6]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[8]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[8]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[9]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Protein Interaction/Cellular Processes	[8]
Cathepsin B (CTSB)	OTP9G5QB	CATB_HUMAN	Gene/Protein Processing	[10]
Cathepsin D (CTSD)	OTQZ36F3	CATD_HUMAN	Gene/Protein Processing	[10]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[11]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[12]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[13]

References

• [1] Drug information of Amodiaquine, 2008. eduDrugs.
• [2] Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
• [3] Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84.
• [4] Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
• [5] Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007 Aug;82(2):197-203.
• [6] Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: possible implications for susceptibility to amodiaquine-induced liver toxicity. Toxicol Lett. 2017 Jun 5;275:83-91.
• [7] The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
• [8] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [9] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [10] The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. Autophagy. 2013 Dec;9(12):2087-102. doi: 10.4161/auto.26506. Epub 2013 Oct 8.
• [11] High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002 Jun;23(6):949-57. doi: 10.1093/carcin/23.6.949.
• [12] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [13] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [14] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [15] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [16] Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
• [17] Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
• [18] Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
• [19] Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
• [20] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [21] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [22] A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
• [23] Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
• [24] Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
• [25] Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
• [26] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [27] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [28] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [29] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [30] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [31] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [32] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [33] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [34] Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
• [35] Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
• [36] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [37] Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
• [38] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [39] Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
• [40] acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
• [41] Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
• [42] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [43] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [44] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [45] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [46] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [47] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [48] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [49] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [50] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [51] The inducibility of human cytochrome P450 1A by environmental-relevant xenobiotics in the human hepatoma derived cell line HepG2. Environ Toxicol Pharmacol. 2009 Nov;28(3):370-8.
• [52] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [53] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [54] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [55] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [56] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [57] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [58] Red clover aryl hydrocarbon receptor (AhR) and estrogen receptor (ER) agonists enhance genotoxic estrogen metabolism. Chem Res Toxicol. 2017 Nov 20;30(11):2084-2092.
• [59] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [60] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [61] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [62] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [63] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [64] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [65] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [66] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [67] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [68] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [69] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [70] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [71] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [72] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [73] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [74] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [75] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [76] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [77] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [78] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [79] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [80] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [81] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [82] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [83] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [84] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [85] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [86] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [87] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [88] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [89] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [90] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [91] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [92] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [93] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [94] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
• [95] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [96] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [97] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [98] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [99] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [100] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [101] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [102] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
• [103] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [104] Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer. 2004 Mar 20;109(2):167-73. doi: 10.1002/ijc.11720.
• [105] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [106] The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
• [107] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [108] Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL. Apoptosis. 2006 Oct;11(10):1851-60. doi: 10.1007/s10495-006-9529-6.
• [109] Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line. Cancer Res Treat. 2013 Jun;45(2):126-33. doi: 10.4143/crt.2013.45.2.126. Epub 2013 Jun 30.
• [110] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [111] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [112] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [113] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [114] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [115] Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. J Periodontol. 2000 Jun;71(6):955-60. doi: 10.1902/jop.2000.71.6.955.
• [116] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [117] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [118] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [119] A role for the autophagy regulator Transcription Factor EB in amiodarone-induced phospholipidosis. Biochem Pharmacol. 2015 Jun 1;95(3):201-9. doi: 10.1016/j.bcp.2015.03.017. Epub 2015 Apr 13.
• [120] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [121] Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006 Jan;97(1):64-71.
• [122] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [123] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [124] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [125] Proton pump inhibitors interfere with the anti-tumor potency of RC48ADC. Toxicol In Vitro. 2022 Mar;79:105292. doi: 10.1016/j.tiv.2021.105292. Epub 2021 Dec 3.
• [126] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [127] Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism. Cancer Res. 2008 Jul 1;68(13):5291-300. doi: 10.1158/0008-5472.CAN-08-0222.
• [128] Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. Neurochem Res. 2012 Feb;37(2):370-80. doi: 10.1007/s11064-011-0620-1. Epub 2011 Oct 4.
• [129] Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
• [130] Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization. Autophagy. 2016 Nov;12(11):2213-2229. doi: 10.1080/15548627.2016.1213927. Epub 2016 Sep 16.
• [131] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [132] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [133] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [134] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [135] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [136] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [137] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [138] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [139] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [140] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [141] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [142] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [143] Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
• [144] 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
• [145] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [146] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [147] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [148] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [149] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [150] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [151] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [152] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [153] Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
• [154] Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
• [155] Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
• [156] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [157] Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
• [158] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [159] Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
• [160] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [161] A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
• [162] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [163] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [164] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [165] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [166] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [167] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [168] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [169] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [170] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [171] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [172] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [173] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [174] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [175] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [176] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [177] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [178] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [179] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [180] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [181] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [182] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [183] Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med. 2004 Jan;10(1):40-7. doi: 10.1038/nm969. Epub 2003 Dec 14.
• [184] Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
• [185] Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
• [186] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [187] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [188] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [189] The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study. Toxicol In Vitro. 2020 Aug;66:104884. doi: 10.1016/j.tiv.2020.104884. Epub 2020 May 8.
• [190] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [191] Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. Br J Cancer. 2011 Jul 12;105(2):221-30. doi: 10.1038/bjc.2011.229.
• [192] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [193] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [194] Anti-cancer properties of glucosamine-hydrochloride in YD-8 human oral cancer cells: Induction of the caspase-dependent apoptosis and down-regulation of HIF-1. Toxicol In Vitro. 2012 Feb;26(1):42-50. doi: 10.1016/j.tiv.2011.10.005. Epub 2011 Oct 13.
• [195] Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res. 2012 Dec 15;18(24):6690-701. doi: 10.1158/1078-0432.CCR-12-0770. Epub 2012 Oct 18.
• [196] Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24.
• [197] Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci. 2000;909:233-46. doi: 10.1111/j.1749-6632.2000.tb06685.x.
• [198] Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res. 2001 May;92(5):524-8. doi: 10.1111/j.1349-7006.2001.tb01125.x.
• [199] CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
• [200] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [201] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [202] Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
• [203] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [204] Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.
• [205] A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun. 2001 Mar 2;281(3):810-4. doi: 10.1006/bbrc.2001.4422.
• [206] Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
• [207] Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
• [208] Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
• [209] An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
• [210] Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
• [211] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [212] An evaluation of myeloperoxidase-mediated bio-activation of NSAIDs in promyelocytic leukemia (HL-60) cells for potential cytotoxic selectivity. Toxicol Lett. 2017 Oct 5;280:48-56.
• [213] Differentiation between stoichiometric and anticatalytic antioxidant properties of benzoic acid analogues: a structure/redox potential relationship study. Chem Biol Interact. 2013 Nov 25;206(2):194-203.
• [214] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [215] Effect of anti-rheumatic drugs on the release of lysosomal enzymes from human leukocytes. Z Rheumatol. 1984 Jan-Feb;43(1):23-6.
• [216] Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. Cancer Res. 2005 Sep 1;65(17):7847-55. doi: 10.1158/0008-5472.CAN-05-1053.
• [217] Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis. Clin Immunol. 2007 Feb;122(2):187-93. doi: 10.1016/j.clim.2006.09.011. Epub 2006 Oct 27.
• [218] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [219] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [220] Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
• [221] Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
• [222] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [223] Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
• [224] Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
• [225] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [226] Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
• [227] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [228] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [229] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [230] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [231] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [232] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [233] Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
• [234] Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
• [235] Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
• [236] Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
• [237] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [238] Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
• [239] Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
• [240] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [241] Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
• [242] Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. doi: 10.1124/jpet.105.086504. Epub 2005 Apr 21.
• [243] Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
• [244] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [245] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [246] In vitro metabolism of helenalin and its inhibitory effect on human cytochrome P450 activity. Arch Toxicol. 2022 Mar;96(3):793-808. doi: 10.1007/s00204-021-03218-6. Epub 2022 Jan 6.
• [247] Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes. Chem Res Toxicol. 2015 Feb 16;28(2):268-78.
• [248] Functional characterization of CYP2A13 polymorphisms. Xenobiotica. 2007 Dec;37(12):1439-49. doi: 10.1080/00498250701666265.
• [249] Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes. Chem Res Toxicol. 2019 Jun 17;32(6):1268-1280. doi: 10.1021/acs.chemrestox.9b00078. Epub 2019 Apr 17.
• [250] Structure-Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6. Chem Res Toxicol. 2016 Jun 20;29(6):1029-40. doi: 10.1021/acs.chemrestox.6b00083. Epub 2016 May 12.
• [251] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
• [252] Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther. 2006 Dec;319(3):1162-71.
• [253] Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8.
• [254] Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics. 2009 Oct;19(10):800-12. doi: 10.1097/FPC.0b013e3283317ab5.
• [255] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [256] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [257] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [258] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [259] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [260] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [261] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [262] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [263] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [264] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [265] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.